Immune checkpoint therapy (ICT) represents a transformative advance in cancer immunotherapy, enabling durable tumor control in select patients. However, primary and acquired resistance to ICT remain significant obstacles, often driven by the tumor microenvironment (TME). Recent research from the University of California, San Diego, published in the May 20, 2026 edition of Nature Communications, elucidates a novel mechanism of resistance involving microRNA-25 (miR-25) and its regulation of Syndecan-3 (SDC3). [1]
Immune checkpoint therapy has revolutionized cancer care by enhancing the immune system’s ability to recognize and eliminate tumor cells. Despite these successes, a considerable proportion of patients experience limited or transient responses, with resistance frequently arising from immunosuppressive features within the TME. Addressing the molecular drivers of this resistance is imperative for expanding the reach and efficacy of ICT.
The Role of MicroRNAs in the Tumor Microenvironment
MicroRNAs (miRNAs) are small, non-coding RNA molecules that regulate gene expression post-transcriptionally. Their involvement in cancer progression and immune evasion is increasingly recognized, yet their specific contributions to ICT resistance have remained unclear. The UC San Diego team, led by Tariq Rana, Ph.D. focused on miR-25 after observing its differential expression in tumors responsive to immunotherapy.
Key Findings
miR-25 Deletion Sensitizes Tumors to Immunotherapy
In multiple syngeneic mouse cancer models, genetic deletion of miR-25 did not impact baseline tumor growth but significantly enhanced response to ICT. This suggests that miR-25 is dispensable for tumor proliferation yet pivotal in modulating immune-mediated tumor control.
Remodeling the Tumor Microenvironment
Single-cell transcriptomic analyses revealed that miR-25 deficiency reshapes the TME, activating both innate and humoral immune pathways:
- Tumor-Associated Macrophages (TAMs): Increased expression of major histocompatibility complex class II (MHC II) molecules, enhancing antigen presentation.
- Cancer-Associated Fibroblasts (CAFs): Upregulated classical complement signaling, shifting CAFs toward an inflammatory phenotype (iCAF). This transformation reduces immunosuppressive crosstalk with TAMs and promotes a pro-inflammatory environment supportive of anti-tumor immunity.
Syndecan-3 as a Functional Target
Mechanistically, miR-25 was shown to repress Syndecan-3 (SDC3) in response to interferon-γ (IFN-γ). CRISPR-mediated editing of the miR-25 binding site in the Sdc3 gene restored SDC3 expression and recapitulated the therapeutic benefits of miR-25 deletion. This identifies the miR-25–SDC3 axis as a critical determinant of ICT resistance.
These findings highlight miR-25 as a molecular shield that protects tumors from immune attack by orchestrating a suppressive TME. Targeting the miR-25–SDC3 pathway offers a promising strategy to convert immunologically ‘cold’ tumors into ‘hot’ tumors that are more amenable to ICT. Further preclinical and clinical studies are warranted to develop miR-25 inhibitors or SDC3 modulators as adjuncts to existing immunotherapies.
Conclusion
The UC San Diego study provides compelling evidence that miR-25–mediated repression of SDC3 underlies a key mechanism of immune checkpoint therapy resistance. Therapeutic targeting of this pathway may broaden the patient population benefiting from ICT and represents a significant step toward overcoming the challenge of immunotherapy-resistant cancers.
__
Reference
[1] Zhu Z, Han W, Deng Y, Jia Z, Baidwan G, Wu L, Jakhmola S, Wang T, Logeswaran D, Wen J, Sun AY, Bray B, Li N, Wang L, Hui H, Wu J, Patel SP, Rana TM. microRNA-25 drives immune checkpoint therapy resistance by repressing innate and humoral immunity via Syndecan-3. Nat Commun. 2026 May 20. doi: 10.1038/s41467-026-73339-y. Epub ahead of print. PMID: 42161938.
Featured image: University of San Diego Hahn School of Nursing and Health Science, Alcala Park, San Diego, CA, USA. Photo courtesy: 2022 – 2026 © Unsplash License.Used with permission.
DOI
 represents a transformative advance in cancer immunotherapy, enabling durable tumor control in select patients. However, primary and acquired resistance to ICT remain significant obstacles, often driven by the tumor microenvironment (TME). Recent research from the University of California, San Diego, published in the May 20, 2026 edition of Nature Communications, elucidates a novel mechanism of resistance involving microRNA-25 (miR-25) and its regulation of Syndecan-3 (SDC3). This article summarizes key findings and discusses their implications for overcoming immunotherapy resistance.){kind=link}